TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06775392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bromelain-quercetin gel
Description: bromelain-quercetin gel is prepared from capsules in laboratory

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine gel
Description: chlorhexidine gel is prepared in laboratory

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SRP
Description: Scaling and root planing was done with ultra sonic and hand scaling
Study: NCT06775665

Intervention type: OTHER
Intervention: No interventions were applied to the patients.
Description: No interventions were applied to the patients.
Study: NCT06775730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensitrelvir
Description: Ensitrelvir will be administered per schedule specified in the arm description.
Study: NCT06776796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Personalized Normative Feedback Intervention Targeting Alcohol Misuse
Description: This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse. It is tailored by the identities chosen by participants including gender, race/ethnicity, and sexual orientation. The intervention is a modified version of an existing evidence-based program, the Brief Alcohol Screening and Intervention for College Students (BASICS) (Dimeff, et. al, 1999).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mental Health and Substance Use Resources
Description: Participants were directed to a website where information regarding mental health and substance use may be found.
Study: NCT06776224

Intervention type: OTHER
Group type: OTHER
Intervention: Measurement of retinal vascular density and visual cognition
Description: During the same visit, we will perform OCT-angiography (10 minutes) and evaluate visual cognition with an eye-tracker (20 minutes)
Study: NCT06777264

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological: single dose of Inaticabtagene autoleucel
Description: Inaticabtagene autoleucel will be transfusioned intravenously at the recommended dose of 0.5×10\^8 (ranging 0.2-0.6×10\^8) viable CAR-T cells.
Study: NCT06776536

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transrectal ultrasound of the bowel endometriosis during operation
Description: This is a prospective, single-arm study aimed at evaluating the efficacy of intraoperative transrectal ultrasound (TRUS) in assessing rectal infiltration depth and length in patients with bowel involvement due to deep infiltrative endometriosis (DIE). The study will include 15-40 female patients aged 18-55, diagnosed with intestinal endometriosis preoperatively using transvaginal ultrasound and MRI, and scheduled for bowel resection.~Preoperative evaluations will include pelvic examination, imaging (TVUS and MRI), and pain assessment using a visual analog scale (VAS). During surgery, TRUS will be used to measure the depth and length of rectal involvement, and findings will be compared with preoperative MRI results.
Study: NCT06776770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Phase I: Cohort 1: Adebrelimab 10 mg/kg Q3W plus capecitabine and oxaliplatin (XELOX regimen); 21-day treatment cycle; Cohort 2: Adebrelimab 1200 mg or 20 mg/kg Q3W plus capecitabine and oxaliplatin (XELOX regimen); 21-day treatment cycle.~Phase II: Adebrelimab (RP2D, Q3W) + (XELOX regimen), with a 3-week (21-day) treatment cycle.~XELOX regimen：Oxaliplatin 130 mg/m2 iv.gtt d1，Capecitabine 1,000 mg/m2 p.o.b.i.d.d1\~14.
Study: NCT05073835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 3 mg
Description: Semaglutide 2.4 mg/week, subcutaneous injection. Treatment dose: 16 weeks of dose escalation + 52 weeks of study dose (i.e., 2.4 mg/week).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05631379

Intervention type: OTHER
Intervention: Measurement of body composition with computed tomography (CT)
Description: The cross section of the third lumbar vertebrae in the CT scan images of the patients will be analyzed for assessment of body composition parameters including skeletal muscle area (SMA), muscle radiation attenuation (MRA), visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT)

Intervention type: DIAGNOSTIC_TEST
Intervention: GLIM malnutrition criteria
Description: GLIM criteria (Global Leadership Initiative on Malnutrition) will be applied to assess malnutrition

Intervention type: DIAGNOSTIC_TEST
Intervention: GLIM malnutrition criteria
Description: GLIM criteria (Global Leadership Initiative on Malnutrition) will be applied to assess malnutrition

Intervention type: DIAGNOSTIC_TEST
Intervention: EWGSOP2 sarcopenia criteria
Description: EWGSOP2 criteria (Writing Group for the European Working Group on Sarcopenia in Older People 2) will be followed to determine the diagnosis of sarcopenia
Study: NCT05269628

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo CBD
Description: Placebo solution will be taken twice per day, using the same dosing regimen as described for Epidiolex®.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo THC
Description: Placebo capsules will be taken twice per day in the same schedule and manner as active dronabinol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo THC
Description: Placebo capsules will be taken twice per day in the same schedule and manner as active dronabinol.
Study: NCT05631379

Intervention type: DIAGNOSTIC_TEST
Intervention: ESPEN-EASO criteria for sarcopenic obesity
Description: The European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO) consensus criteria from 2018 will be applied to assess sarcopenic obesity

Intervention type: DIAGNOSTIC_TEST
Intervention: Prognostic Nutritional Index (PNI)
Description: Prognostic Nutritional Index is diagnostic test based on serum albumin level and total lymphocyte count

Intervention type: DIAGNOSTIC_TEST
Intervention: Prognostic Nutritional Index (PNI)
Description: Prognostic Nutritional Index is diagnostic test based on serum albumin level and total lymphocyte count

Intervention type: DIAGNOSTIC_TEST
Intervention: The high-sensitivity modified Glasgow prognostic score
Description: The high-sensitivity modified Glasgow prognostic score (Hs-mGPS) is an inflammation-based score consisted of C-reactive protein level and serum albumin

Intervention type: DIAGNOSTIC_TEST
Intervention: The high-sensitivity modified Glasgow prognostic score
Description: The high-sensitivity modified Glasgow prognostic score (Hs-mGPS) is an inflammation-based score consisted of C-reactive protein level and serum albumin
Study: NCT06777459

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice
Description: Nitrate-rich beetroot juice, \~750 mg NO3- /d
Study: NCT06776887

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Wii Fit group will receive the Wii Fit program for 30 minutes in addition to SPTP for 60 minutes, whereas. The intervention was 3 sessions a week for 12 weeks
Description: The Wii Fit group will receive the Wii Fit program for 30 minutes in addition to SPTP for 60 minutes, whereas. The intervention was 3 sessions a week for 12 weeks.~The control group will receive standard physical therapy program (SPTP) only 3 sessions a week for 12 weeks .

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Wii Fit group will receive the Wii Fit program for 30 minutes in addition to SPTP for 60 minutes, whereas. The intervention was 3 sessions a week for 12 weeks
Description: The Wii Fit group will receive the Wii Fit program for 30 minutes in addition to SPTP for 60 minutes, whereas. The intervention was 3 sessions a week for 12 weeks.~The control group will receive standard physical therapy program (SPTP) only 3 sessions a week for 12 weeks .
Study: NCT06777251

Intervention type: OTHER
Group type: OTHER
Intervention: analysis of predictive factors of IF in patients with Crohn's disease through the characterization of multiomics parameters
Description: The study includes an initial evaluation in which faecal samples will be collected, a blood sample will be taken and an ileocolonoscopy with biopsies will be performed (additional biopsy in conjunction with a biopsy from clinical practice for study-specific analyses).~Patients will then be reevaluated nine months after the initial evaluation. In particular, fecal, blood and additional biopsy samples will be collected in conjunction with clinical practice biopsy and all treatment modifications will be recorded.
Study: NCT05041309

Intervention type: BIOLOGICAL
Intervention: Axicabtagene Ciloleucel
Description: No investigational product will be administered

Intervention type: BIOLOGICAL
Intervention: Brexucabtagene Autoleucel
Description: No investigational product will be administered

Intervention type: BIOLOGICAL
Intervention: Anitocabtagene autleucel
Description: No investigational product will be administered

Intervention type: BIOLOGICAL
Intervention: KITE-753
Description: No investigational product will be administered

Intervention type: BIOLOGICAL
Intervention: KITE-197
Description: No investigational product will be administered

Intervention type: BIOLOGICAL
Intervention: KITE-363
Description: No investigational product will be administered
Study: NCT05476601

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CMAP Plus
Description: The CMAP Plus intervention will be delivered individually, weekly over a period of 12 weeks.
Study: NCT05036070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Model C0001
Description: Investigational intraocular lens replaces the natural lens removed during cataract surgery in both eyes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Model ZCB00
Description: Control intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
Study: NCT06241677

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alteplase or tenecteplase
Description: Either alteplase (0.6 or 0.9mg/kg, maximum dosage 90mg) or tenecteplase (0.25mg/kg, maximum dosage 25mg) will be given
Study: NCT05626920

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Disulfiram 250 mg
Description: Disulfiram treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment
Study: NCT06545045

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Strategy Training (MCST)
Description: The MCST group will follow procedures for the Cognitive Orientation to daily Occupational Performance intervention. First, five functional, everyday life goals are identified collaboratively by the participant and interventionist. In the second meeting, the therapist introduces the approach to the subject and teach a global cognitive strategy (i.e., GOAL-PLAN-DO-CHECK). In all subsequent sessions, this strategy is used as the main problem-solving framework to facilitate skill acquisition. The subject identifies a GOAL, and then is guided by the therapist to discover a PLAN to potentially achieve the goal. The subject is then asked to DO the plan (if feasible during the therapy session otherwise asked to complete at home prior to the next treatment session), and subsequently to CHECK to see if the plan worked, i.e. the goal was achieved. This process is repeated until satisfactory performance is met for each established goal.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactive Control Group
Description: Weekly contact will be made via telephone call to (1) maintain study engagement, (2) introduce weekly social contact with researchers, mimicking some of the potential incidental effects of the experimental group, and (3) ascertain what, if any, additional steps participants have taken to reduce cognitive symptoms. The content of each of these meetings will be tracked in intervention notes.
Study: NCT06645756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meal
Description: Test meal consisting of fries, chicken nuggets and eggs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meal
Description: Test meal consisting of fries, chicken nuggets and eggs
Study: NCT06646315

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Intervention
Description: The Early Intervention consists of the proper attention given to those patients who participate in a Phase I Clinical Trial. The attention will be based on a monthly assessment of their physical, psychological/emotional symptoms and, also their sociofamiliar needs. After having discussed patients's needs in a multidisciplinary committee, each professional (paliiative physician, clinical psychologist and/or wocial orker) will proportionate them the required attention in order to increase their quality of life.
Study: NCT04542551

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dilation 60-Fr non stricture
Description: Dilation of patients with subjective dysphagia and normal endoscopy

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham dilator for patients with subjective dysphagia and normal endoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non severe stricture - dilation with 60-Fr
Description: Dilation of non severe stricture with 60-Fr dilator

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non severe stricture - dilation with 46-Fr
Description: Dilation of non severe stricture with 46-Fr dilator

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Severe stricture - dilation with 51-Fr
Description: Dilation of a severe stricture with 51-Fr dilator

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Severe stricture - dilation with 42-Fr
Description: Dilation of a severe stricture with 42-Fr dilator
Study: NCT04296409

Intervention type: OTHER
Intervention: Turkish Deglutition Handicap Index
Description: Swallowing function will be evaluated by the Turkish Deglutition Handicap Index.
Study: NCT05473221

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD33 CAR-T
Description: CD33 CAR-T is a new type CAR-T cells therapy for patients with acute myeloid leukemia.
Study: NCT06367426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDN-A-0101 (SAD)
Description: Investigational drug~* Development name: DDN-A-0101~* Main ingredient and content: DDN-A-0101 (Houttuynia cordata dry extract, 150.0 mg)~* Formulation and properties: Light brown circular film coating tablet~* Storage method: airtight container, stored at room temperature (1-30 degree celsius)~* Administration method: single dose oral administration (300, 600, 900, 1200, 1500 mg)~* Expiration date: 36 months from the date of manufacture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDN-A-0101 (MAD)
Description: Investigational drug~* Development name: DDN-A-0101~* Main ingredient and content: DDN-A-0101 (Houttuynia cordata dry extract, 150.0 mg)~* Formulation and properties: Light brown circular film coating tablet~* Storage method: airtight container, stored at room temperature (1-30 degree celsius)~* Administration method: repeated oral administration (150, 300, 450, 600 mg, 2 times/day, 2 weeks of repeated administration)~* Expiration date: 36 months from the date of manufacture

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (SAD)
Description: Placebo drug~* Development name: placebo of DDN-A-0101~* Formulation and properties: Light brown circular film coating tablet~* Storage method: airtight container, stored at room temperature (1-30 degree celsius)~* Administration method: single dose oral administration (300, 600, 900, 1200, 1500 mg)~* Expiration date: 36 months from the date of manufacture

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (MAD)
Description: Placebo drug~* Development name: placebo of DDN-A-0101~* Formulation and properties: Light brown circular film coating tablet~* Storage method: airtight container, stored at room temperature (1-30 degree celsius)~* Administration method: repeated oral administration (150, 300, 450, 600 mg, 2 times/day, 2 weeks of repeated administration)~* Expiration date: 36 months from the date of manufacture
Study: NCT06585007

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Progression-directed therapy (stereotactic body radiation therapy)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: metastasectomy
Description: Progression-directed therapy (metastasectomy)
Study: NCT06584981

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pectoral nerve block (PECS II), parasternal and serratus plane blocks
Description: These block applications are performed under sterile conditions under the guidance of ultrasonography

Intervention type: OTHER
Group type: OTHER
Intervention: analgesic
Description: Analgesia needs of patients who do not receive blockade are met with intravenous drugs.
Study: NCT05924971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81Mg Ec Tab
Description: Aspirin 81 mg 1 tablet by mouth. Participants randomized to receive aspirin in addition to standard blood pressure management will receive the study medication nightly at 20:00, with first dose initiated within 24 hours of delivery.
Study: NCT06043427

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80 mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m²

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab
Description: 8 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: 8 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanidatamab
Description: Dose and schedule to be assigned at enrollment
Study: NCT06402344

Intervention type: OTHER
Intervention: Hormonal implant
Description: History of at least 1 hormonal implant with gestrinone in the last 6 months, applied by the participant's private doctor.

Intervention type: OTHER
Intervention: Control group
Description: Young women who never used any hormonal implant.
Study: NCT06058832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-intensity Shockwave Therapy
Description: patients will receive 6 sessions, once per week of low-intensity extracorporeal shock wave with the following parameters: - 3000 SWs (energy intensity of 0.09 mJ/mm2) to each of five different sites: three along the penile shaft and two at the crural level plus Sildenafil 25mg of daily dose and 50mg on-demand dose one hour before intercourse for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kegel Exercises
Description: * The patient was asked to perform short (1 second) and long-lasting (6-10 seconds) contractions of the target muscles. Later, the exercises will do with the patient sitting or standing.~* Patient asked to repeat the contractions daily. Each patient performed 15 short and 15 long-lasting contractions in a prone, sitting, or standing position. Patients asked to do 30 contractions in the morning 30 contractions in the evening
Study: NCT04824794

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN3014
Description: GEN3014 is administered by IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab
Description: Daratumumab is administered by SC injections.
Study: NCT06190301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intralesional Rituximab Injection

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Involved Site Radiation Therapy
Description: Involved Site Radiation Therapy
Study: NCT06529419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8630
Description: The drug will be administered by inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8630
Description: The drug will be administered by inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8630
Description: The drug will be administered by inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be administered by inhalation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inhaler
Description: The drug/placebo will be administered by inhalation using the inhaler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inhaler
Description: The drug/placebo will be administered by inhalation using the inhaler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inhaler
Description: The drug/placebo will be administered by inhalation using the inhaler

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Inhaler
Description: The drug/placebo will be administered by inhalation using the inhaler
Study: NCT06544655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986484
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986484
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986484
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986484
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT06350097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Arm 1: Osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion.~Arm 2: Osimertinib 80 mg QD as oral tablet .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: Arm 1: Osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion.~Arm 2: Osimertinib 80 mg QD as oral tablet .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab Deruxtecan
Description: Osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion.
Study: NCT06082518

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monoplace Hyperbaric Chamber (Class III medical device).
Description: 40 hyperbaric oxygen therapy (HBOT) treatments (90 minute exposures at 2 atmospheres (ATM) per treatment), scheduled daily from Monday to Friday (i.e., 5 treatments per week) until treatments are completed (approximately 8 weeks). Treatments will be delivered in a medical grade, Health Canada-approved monoplace hyperbaric chamber and overseen by specialist hyperbaric physicians and a Certified Hyperbaric Technologist.~Device is being used in manner consistent with approved usage in Canada.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monoplace Hyperbaric Chamber (Class III medical device).
Description: 40 hyperbaric oxygen therapy (HBOT) treatments (90 minute exposures at 2 atmospheres (ATM) per treatment), scheduled daily from Monday to Friday (i.e., 5 treatments per week) until treatments are completed (approximately 8 weeks). Treatments will be delivered in a medical grade, Health Canada-approved monoplace hyperbaric chamber and overseen by specialist hyperbaric physicians and a Certified Hyperbaric Technologist.~Device is being used in manner consistent with approved usage in Canada.